Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344654 | 1.00 | TSHR (0.42) | TSHRTP53EGLN1EGLN3HCAR2 | |
| SCHEMBL18613105 | 0.74 | HCAR2 (0.48) | TSHRTP53EGLN1EGLN3HCAR2 | |
| SCHEMBL12282953 | 0.72 | — | — | |
| Maleic Acid SCHEMBL161203 | 0.67 | — | — | |
| Fumaric Acid SCHEMBL187959 | 0.67 | — | — | |
| SCHEMBL1257748 | 0.67 | — | — | |
| SCHEMBL11803247 | 0.67 | — | — | |
| SCHEMBL16792413 | 0.67 | — | — | |
| SCHEMBL2440721 | 0.67 | — | — | |
| SCHEMBL16777471 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289104-A1 | ALIPHATIC AMINO ACID BIOSYNTHESIS INHIBITORS AND A METHOD OF SYNTHESIZING THE SAME | Sardari, Soroush (IR) | 2013-10-31 | — | — | US | claimed |
| US-8569361-B1 | Aliphatic amino acid biosynthesis inhibitors and a method of synthesizing the same | SARDARI SOROUSH (IR) | 2013-10-29 | — | — | US | claimed |
| US-11129819-B2 | Fumarate analogs and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| CN-106573901-B | Fumarate analogues and their use in the treatment of autoimmune or inflammatory diseases | 参宿七制药股份有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200155531-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2020-05-21 | — | — | US | disclosed |
| US-20180071271-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-03-15 | — | — | US | disclosed |
| US-9801866-B2 | Fumarate analogs and uses thereof | Rigl Pharmaceutical, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170174922-A1 | CONDUCTIVE MATERIAL AND SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-06-22 | — | — | US | disclosed |
| EP-3177599-A1 | FUMARATE ANALOGS AND USES THEREOF IN THE TREATMENT OF AN AUTOIMMUNE DISEASE OR AN INFLAMMATORY DISEASE | Rigel Pharmaceuticals, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170130071-A1 | CONDUCTIVE MATERIAL AND SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170130070-A1 | CONDUCTIVE MATERIAL AND SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-03-09 | — | — | US | disclosed |
| US-9360753-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| WO-2016022434-A1 | FUMARATE ANALOGS AND USES THEREOF IN THE TREATMENT OF AN AUTOIMMUNE DISEASE OR AN INFLAMMATORY DISEASE | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-9164383-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-20130289104-A1 | ALIPHATIC AMINO ACID BIOSYNTHESIS INHIBITORS AND A METHOD OF SYNTHESIZING THE SAME | Sardari, Soroush (IR) | 2013-10-31 | — | — | US | disclosed |
| US-8569361-B1 | Aliphatic amino acid biosynthesis inhibitors and a method of synthesizing the same | SARDARI SOROUSH (IR) | 2013-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071271-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | TSHR 4654/4885TP53 570/4885EGLN1 946/4885 |
| US-20130289104-A1 | ALIPHATIC AMINO ACID BIOSYNTHESIS INHIBITORS AND A METHOD OF SYNTHESIZING THE SAME | DDC, BCAT2, BCAT1 | TSHR 3516/4885TP53 3528/4885EGLN1 1341/4885 |
| US-20200155531-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | TSHR 4654/4885TP53 570/4885EGLN1 946/4885 |
| US-11129819-B2 | Fumarate analogs and uses thereof | FH, GLS, FPGS | TSHR 4654/4885TP53 570/4885EGLN1 946/4885 |
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | TSHR 4654/4885TP53 570/4885EGLN1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.